pPuro.HRE>GFP was generated using the lentiviral expression plasmid PURO.Cre (Addgene, plasmid no. 17408) as a backbone. Eight repeats of the hypoxia-responsive element (5′-GCCCTACGTGCTGTCTCACACAGC-3′) from the 3′ enhancer region of the human EPO gene were amplified by polymerase chain reaction (PCR), fused to a TATA box/linker (5′-TCTAGAGGGGTATATAATGGAAGCTC-′3), and amplified with flanking restriction enzyme sites (5′ Xho I/3′ Sma I). The constructed fragment, termed HRE, was inserted into PURO.Cre, replacing the original PGK promoter. Subsequently, EGFP was amplified by PCR from pLNT/SFFV hNIS-GFP (85) with flanking Sma I/Kpn I sites and subcloned into the intermediate construct replacing Cre, thereby providing the final construct pPuro.HRE>GFP. Puromycin (Gibco; 1 μg/ml) was used as the selection antibiotic.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.